ehealth radio network
Getting to know Tenax Therapeutics

Getting to know Tenax Therapeutics

January 21, 2021

 

TENX_CEO_Headshot.jpeg

 

Anthony DiTonno CEO of Tenax Therapeutics, a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs joins eHealth Radio and the Health News and Pharmaceutical Channels.


Listen to interview with host Eric Michaels & guest Anthony DiTonno discuss the following:

  1. Can you tell me a bit about yourself and how you got interested in the healthcare and pharmaceutical industry?
  2. What products are in the pipeline?
  3. Could you please tell us about Tenax's HELP study?
  4. Please let us and talk a little about Levosimendan.

Anthony A. DiTonno has served as CEO since 2018 and as a director since December 2011. From 2013 until filling the role as Tenax CEO, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices.

From April 2003 until December 2011, Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area (“Neurogesx”). During his time at Neurogesx, Mr. DiTonno also served on its board of directors.

Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financing, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union.

Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories.

Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph’s University.

 

Tenax_Therapeutics_LOGO7ml5s.png

 

Website: www.tenaxthera.com

New Breakthroughs to Avoid Shortage of Treatment for Those with Inherited COPD

New Breakthroughs to Avoid Shortage of Treatment for Those with Inherited COPD

May 4, 2015


Mr. Jeffrey Davis, COO of PlasmaTech BioPharmaceuticals, a Dallas & New York-based biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care joins eHealth Radio and the Pharamceutical, Health Care & News Channels.


Listen to interview with host Eric Michaels & guest Mr. Jeffrey Davis discuss the following:

  • What is Inherited COPD? Who does it affect?
  • Why does the World Health Organization and the American Thoracic Society recommend that every individual diagnosed with COPD be tested for Alpha-1?
  • How do these patients get the Alpha-1 Anti-trypsin that they need?
  • Why could we see a shortage of this drug in a few years?
  • How can your Company’s technology change that?
  • What resources are available for those with Inherited COPD?


Duration: 8:10


About PlasmaTech Biopharmaceuticals, Inc.


PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.


Jeffrey B. Davis holds a B.S. in biomedical engineering from Boston University and an MBA degree from the Wharton School, University of Pennsylvania.  Mr. Davis has held a variety of c-level executive positions in the biotechnology industry, and is currently a Director and Chief Operating Officer of PlasmaTech Biopharmaceuticals, Inc.


Mr. Davis was previously CEO of Access Pharmaceuticals, Inc., and has previously served in a variety of senior investment banking and management positions. Mr. Davis was an investment banker with various Deutsche Bank AG banking organizations, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff, and at Philips Medical Systems North America.



Website: www.plasmatechbio.com

Play this podcast on Podbean App